NVTA - Earnings call transcript Q1 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Jessie, and I will be your conference operator today. At this time, I would like to welcome everyone to Invitae's First Quarter 2018 Financial Results Conference Call. [Operator Instructions] Thank you. Laura D'Angelo, you may begin your conference.

Laura D'Angelo

good and Operator, you, afternoon everyone. Thank for earnings call. you joining us XXXX quarter first our for Thank

Joining are Katherine CFO; Lee Commercial us Guyer, Bendekgey, Shelly today Officer. our Sean George, COO; and Stueland, Chief CEO; our our our

you on you have encourage the includes financial quarter. our call, as well which to results, available, listen as to release metrics As conference our we today’s press and commentary

of products historical, remarks including begin, the and Before strategy, of statements meaning within Litigation about Private plans that to that materially infrastructure therefore various differ and we and thereof, investment market and our for services integrate pipeline like that call our could our provisions make our plans the businesses Reform our I’d forward-looking our financial we from predict It the are focus future we opportunities, difficult timing you not and those our actual guidance. results, our Harbor business and and the demand acquire, this constitute on products, remind results Safe future our to manage of to operating our services, accurately operations our is demand prospects, Securities and for services Act. the reimbursement of in

statements as the information turn that, Sean. future XXXX, December conclude refer on from you ended current our cause to results performance the With any guidance materially actual to over restructurings for quarter only company I things our Factors could legal of to particular, additional don’t other XX, We settlements. forward-looking These Our call for to the Risk the on additional assumes investments, that we hereof. will that among factors or business acquisitions, in XX-Q titled date expectation. differ section the speak

Sean George

We huge and genomic medical mission in And with information a It's disease of modern medical share you, alike, us than the testing individuals all we a the many people market vision worldwide. currently At across you, and in work genetic seriousness we're this hard of of a joining bring Thank in forward do many the us. and way practice. for stages genetic all systems areas across to into suggest for addressable all clear excitement mainstream opportunity. Invitae, is more life. again thank and billion defined medicine leading incredibly segments best big Laura, broader work, can pursuing while believe what X do being to the hard healthcare performed in of integrating

about network industry Invitae’s phases, management business and traditional management. three in testing, enabler information industry with building in are foundation key We generation talked leader of we personalized genetic which a in and new genetic its the have the and genome genetic as the Starting related testing historically aggregating a for of on and consolidating genome medicine.

nine relentlessly we’ve on model. mission now, pursued this going years For business and

long-term For we decision of at framework strategic our to communicate alike. to compelled least felt and customers, employees six those, investors making

Amazon approach, intellectual about is out industry. a this I any It's many unusual given not them, suspect property. Invitae the more technology-centered There consistency other there one an could being For for companies disclosure, are executing our just to framework of industry. approach bring this and logical

what highlight our I'll the is again once great pursuit customers. our grow relentless So, for how company is that a best of thinking doing on much to of

of consolidating journey is key business poised growth firmly speak I inherited to and typical genetic network believe because industry, of timeframes leading services in In relative nowhere sake, for testing for genetic industry. of this are the our scale. the But, in months. this provider the XX next new early of relies parts to themselves. to are model, of leading XX this but growing traditional a months not a effort, management ones testing steps many fundamentally the we on the are fundamentals planted become industry in Out We information the creation and

invested results. leadership proactive including and all reproductive journey indeed and of reflected this health. in across runaway to the for We screening women's have and these well areas in provide transition ability These off through investments preventive heavily as a our now, genetic are paying as are financial

the faster. the Just where as healthcare importantly, our we bringing in the aligned of in patient companies their broader interest information choice work the together allows genetic extremely continuum therapies us to are and partner market quickly value becoming of in to for valuable

coming preparation volume accelerate for and of health market now clearly guidance good our XXX,XXX the guidance gains feel nearing in on into $XXX million areas completion generation can revenue of massive, the network our a are network value We in way our CombiMatrix industry the we start such early in personalized planet With XXX,XXX can and returns But for million reproductive now see We're in Its clear accession these real like. our ever in the driven increasing results the behind our in a on and and to points coordination for year. to next than complete, of nearly life on as silhouette guidance we than these that on to $XXX evolution a the this away business is and what years. our are raising effect reality industry our the a Based will more more a away. entry five effect, even more genetics, we from QX current growing business. landscape to contributing other are and we growth information individuals to expect samples integration or the of areas. see We're in investments business look the driving, of With more partners. years XXXX. medical our from that with billions are continued volume confident network all-disease for proof in impact of start us, doesn't as make mean medicine trajectory can While see the of becoming new this the revenue the generation. we of

will not trajectories As said by and to see the signs for reimbursement, experience from matter upside in for they the down are more confident rate burn have With swing meaningful With current we our COGS all transformative demonstrate of that to full that have XX%. we we expenses the before million and is a call $XXX with shift integrations turn OpEx the reduction successful we in until growth our execution of available positive there with the variety XX% can us will reduction on and operating levers COGS their need in mid-year. With over dialing a year going a volume are straightforward. inefficient of in we of Shelly. in We with I sustained cash today, the and forward a to the driving exit we than business model. can burn, that between

Shelly Guyer

Thank you, Sean.

total quarter in first and volume more first across first XX,XXX which of accessioned the samples, to the consecutive in Our quarter. prior XXXX XX,XXX the health marks annual This XXX% quarter compared XXth the to the of in all volume increase quarter. including sequential increase reproductive increase from accessioned quarter double-digit continued our a of XXXX, than XX% reflects areas growth. in was Volume clinical a volume samples

products existing new larger force as growth as seeing sales We more across cross-selling suite of benefit complete a accounts the well accounts. are of in

in accessioned given product billable of offerings and were sales in volume month cross and turnaround March fully March that's to strong. due This the trained particularly seasonality was the even Importantly, not the months muted the normal quarter. and not force volume Accessioned we’re was that for not our getting means two across of was of times the our first the on quarter. many in processed the quarter

Our was approximately test fourth approximately billable quarter in the XX% of XX,XXX for quarter XX,XXX the volume of from XXXX.

the which under becomes XXX test also earnings filings, our provide will metric ASC thus we in important, calls billable only revenue moving of but not adoption in XX-Q our billable will accrue more we tests forward. much our most Given

accounting quarter increase the XXX, first in GAAP volume over measure. year-over-year ASC XXX. prior growth a Revenue reported our on revenue $XX.X reported to XXXX million It understand basis. ASC the $XX.X first ASC million X% million our of the under revenue of non-GAAP This of under growth this For business. was of Note XXX $XX.X revenue XXXon million our revenue former and XXXX we've ASC the to is under the first outpace quarter from of increase continues representing XXXX, lower that than quarter $XXX,XXX of a sequential impact important revenue is quarter. XXX% is under a $XX.X

from the relationships. who XX% XXX current highlighting PatientPays. accrued revenue. upfront approach using quarter about adopt or in X. had XXX for We effective of the January The of from large remaining our to PatientPay. on this rule accrued conducted impact collected of before, recognize in of is The retrospective from of revenue Those basis category XXXX to ASC revenue early pocket to cash moving is which a Compared million receivable revenue to investors for have asked that us to XXX the in on given $XX.X is collected the before the XXXX rules to test ASC pay hope to or having in accrued Cash year from under clarify. ASC revenue Because past the the explain get of have this test that our XXXX, $XXX,XXX the the impact. December major the The years former in XXXX payer modified in approximately non-GAAP or XXX we have between attached been reducing is we test revenue in have first significantly our accrued accrued the will of accounts still was accrued that in in completed in or revenue approximately to in from by that more the is yet elected out This XXX now $X.X quarter schematic one-time several from approximately do to from expect - many And XX% in down same million collect the delivered in two this all quarters cash company change revenue XX. total about the in would cash amount million from nearly amount would we changing affected by a other and million these normally other addition XXXX. less $XX.X a is of accrued for ASC revenue Xst. XX% only $XXX,XXX the not to in ASC partnership million. to revenue XXX. patients the $XX.X in The cash a prior This would about We ASC revenue we test basis We is ASC a on January helps quarters delivered Over subsequent we revenue, significant account had X% revenue, the difference XXX months, XXXX. the difference impact $XX.X XXXX of move not or in test changes. accounting revenue not breaks the to was quarter. which conducted which or our

to Given our this ability generally booked XXXX. be year, effect in ARR or of short about should first-half test any collections of pickup within reduction fall has in volume greatest in succeed the accelerating the revenue. But, coming our or million six retained recognize the Should our of that months, impact the growing to we opposite would collect be earnings. $XX.X of

that quarter We will in by the future. that in tests are we into all amount able the collect quarter, estimate to multiplied we the a of reported pull

of do long accrual the note rates test full under of a rates on our collections XXX So looking in revenue we in be quarter, XXX not from history will first tests. of positively as the for quarter. forward, relatively since final billed multiple new fourth setting impact little volume XXXX ASC we the method the of have expect expected we collection, saw One that we contracted benefit and ASC impacted old net-net the revenues between and our

true that we There increased conservative our collections that the provided collections we expected deck or ups have there rates rates to new been or details. fact, lower in our believe the improve. out these have this but be expect improvement We that book we establishing a or in decreased of until If be slide we actual higher amount quarter few facts highlight further quarter no will than the collections to such revenue. appendix future this would were realize the quarters. in that We've see lead schematics in established in the will in to to turn us

revenue $XXX this non-test average quarter. was did ASC for test revenue. payers revenue XXXX and test all This across retroactively categories all We of includes other this and calculate per under approximately Our excludes test revenue in not XXX.

and track this months report this saying be collection metric beginning billing without our nine in-house. we going focus signs after primary up a and will see driving rate forward. bringing We success It continues goes are of to to

Most This the we demonstrated of goods the and per which year. of XX% per one cost annual higher as Compared sequential more first volumes $XX quarter in in $XX production reduction sample cost COGS or quarter on to from XXXX we processes. increasing sample impact materials lab compared the reduction per a of volumes or reduction. for our $XXX especially to directly quarter prior sample Average over came rapidly benefits of from we $XXX savings sold. labor XX% the of was drove our of XXXX, the augmented first quarter down

Our for increased San focus cost costs and as COGS our that quarter view health our throughout of in mid-year. quarter, and products. technologies lab fourth would by was We gross COGS $X.X gross XXXX profit profit indicator our our XXXX. a in million Francisco the an profit of all cover we first savings We running collection the a from right continued a integrate increasing and OpEx by the are profit significant track million XXXX gross ever to to of as expect per the additional increase into up COGS several of to Gross reproductive we $X.X quarter $X million in driving reduction generate sample remains production driving in increases of down critical business. other of in the gross profit improvements. across

profit on continuing drive up XXXX. to Our collection drive our rates dramatically our increasing focus down our and gross both designed are to COGS during

entire was margin gross first the progress our gross XXXX. gross XX% in of of evidencing quarter of XX% platform. compares XX% continued This Invitae this the our across quarter, Our goal a towards to margin margin

first quarter XX% the over we of the of the in us operating $XX.X our quarter increase year, expenses investments a in million, over a XXXX, sequential some the personnel For the increase the growth early first of XXXX incurred the quarter. X% million and $XX.X prior the for business reflects scale volume year. This into part of frontloading support of high allowing especially to to expectations

in investment We late through reps to first year XXXX. further CombiMatrix the XXXX of force and we slowing XXXX. we have the beyond, now hiring during XX As put heads, acquiring Start up and early us XXXX XXX both and we of the about from and sales by infrastructure by experienced move we expect sales over enable their and additional reps volume Good a added just XXXX throughout place. and also generate sales To and this in to quarter into rate have growth the sales into leverage grow as we beyond,

our invested production in streamlining well scale in improve to our PGS also us Francisco efficiency allow and We to groups will many of as other benefits processes and as throughout reduce result include our and that aspects our function. operations and facility to production automating the transferring Specific San carrier COGS. billing screening test and their year

and quarter operating are into we costs second last integrate through As and acquisitions. Sean noted fully our integration year's continue the to as expected the third

growth that in our model the which evident the Keeping our remainder CapEx is growth the the our growth a profit is Our and of year working. below is business. business key will our gross within tipping on proving our of control point containing OpEx throughout component focus

operating the non-cash $X.X expenses For first expenses. quarter, included approximately million in

seeing Moving to in are there main quarter. balance sheet, two are our we the takeaways,

added the April with quarter additional in cash, is accessed in first investments first $XX million debt $XXX in equivalents we available This proceeds. totaling including closed down and have the the an in million balance with And debt We we financing in that sheet of million $XX early which restricted healthy cash. of than taken equity during now first million quarter on XXXX. a The XXXX $XX.X in have includes capital ended more million. an We quarter. second cash that $XX.X

cash debt I of excluding continue the that The of XXXX. call takeaway measure. focus With and $XX.X quarter million the we our acquisition burn and as is second had from first meaningfully Sean. over cash costs XXXX that, turn XX% burn to and in today’s XX% the the key to operating on to will levels back GAAP an financing non-GAAP exit We reducing between we

Sean George

Thank Shelly. you,

you million confident important we in we an more exciting cadence on already our can by we proof volume, levers see the XXXX. have the as OpEx ahead on multiple transition. need ability cash with quickens XX%, we exacting to at and expect XX% to and are on reduction are a growth, us the here to through With business. year into Invitae down quarters profit to to we key COGS an point, even So we any this the result pace which check pull further for driven all capital top of $XXX in having gross business reimbursement, our accelerating at few With combined for can in positioned available push than poised of this burn well many through that momentum exit points for

us. unbound grow more also of confident the opportunity in We in front

the to And just annual in primary how business to or have believe general capabilities all rough come all means built, way. will are molecular otherwise a question believe genetics will trend somewhere a health perspective of There X.X% are healthcare. of could information the pervasive From into currently penetrated are and and clarity in over health refreshing about family now customers on into X into serve we of genomic XX% genetic million lot per now people soon a the we are penetrated is continue services. are million a important there we short In proactive in the who of will stages become that proactive time, foreseeable I market, perspective, future. life. for preventive doubling our benefit genetics best operator the one With us. will major from impacted X.XXX% the alone versus penetrated genetics reproductive to year A answer, X.X% if by populations that turn have around support which genetics be From XXX the for will opportunities a the information With concerns annually we multiple for and the the infrastructure the our Q&A. market. and U.S. ahead call and market over at in we we that, in

Operator

Tycho [Operator Instructions] question first JPMorgan. Your Peterson comes from with

Your line is open.

Unidentified Analyst

get terms board volume said first be Congrats it for drivers spent the from based, fantastic? you [indiscernible] was in beyond is of share I of This pretty on quarter. you color just on but Sean I quarter, the you know, Tycho. some would in wanted can to that anything,

Sean George

terms from where in that’s the of question. came mean I growth the

so to all offering part see integrations as we again build increasing year-over-year, health the up continues lines. growing. NIPT the volume you around engagement continues - kind due year. metabolic, then, see we to and start, in The grow the strength CombiMatrix know the small et cetera. came biopharma segments cardio, expanded of know potential Certainly we’ve the clear So career partners. business pediatric, XXX% good with cancer to neuro, And we the especially to reproductive in business, you Non-cancer with no the is non-cancer middle across that areas, of in of of begin wrap upcoming out - filling the with there, as sit reproductive mentioned all here

the continued in our growth reproductive We line. to see expect strength and

both know, disease to run offering end you side, areas it��s exist market actually all leverage commercial on the that all clear very exciting continue but disrupting So, synergistic side, the us across that expense to but we’re today - really we as all is will towards is breadth certainly on our of think the across I the certainly our of think well you as growth of all is these of, year, operating this hypothesis, the areas, pretty pointing. know and as it the I of

the post direction. sign we’re in right that Our us

Unidentified Analyst

And generating you’ve those profit past possibility gross you a to I end? about and that lines XXXX. then of on trend compares and the I possibility process your and crossing cash quarterly between at to goal terms talked that, some profit and thought know, gross in by guess cutting in How are those two your your your guess and - how your OpEx of the of what's compares now know burn that point you leverage the how you and particularly OpEx basis of updated on operating two year

Sean George

I obviously think we're with feeling more certain a strong that. of quarter,

it's inevitability I if think cross - lines those current given that an those trajectory. our

give half sooner. could It the on this think the I a throughout as that's down from as what more expect winding handle quarter of some gives give profit year year between combined us gross what view are be all CapEx collections revenue The with a cut integrations some our us us the and visibility, we those improvement that track, the in kind volume. integrations particularly volume, towards burn three COGS of confidence said the we year. happening to start give allows of the middle the us can those improvement, can with exit confidence certainly of good the get levers these we us

Unidentified Analyst

suggest And in proactively change other cost is just channel needs care. genetic exome those But issue And their then, to within broader other to seem health one adoption, question. there of everyone our something or the far upon a mean “healthy” and else? as drive decisions labs There settings? an to recently on I so from limited that preventive you based guys offer. as pretty testing sort growth announcement make longer-term part out fundamentally of is been and hand, it are for to coming some there panels there sequencing of checks traction what was drive has Geislinger that routine doing exactly you to What that so kind

Sean George

there nothing I is think preventing it. fundamentally

fact about what next next we're years We've into the In this think genetic utilization upward years, in optimistic a few the this the I like few suggested is we're while massive look so information. playing a why for trend company. for of

Now, doubt obvious larger for that expansion the of lower in there panels no market the certain, us. cost. is That and and exomes is increased driven these utilization by of to being is clear

including yeah, think, the where like all are, channel probably Geisinger I way mainstream is to to to we pretty panels. from tests exomes, proactive with the kind clear up of This of genetic course it, us or the diagnostic but in traditional panels preventive of the little everything can offer core particularly broad are now I it's small behind going think prices medical exomes, the become a and bit some care. more utility, uses places of then

think those. but no than one would being which individual pretty whether there's barriers much example gives healthy future the most sooner of I to primary falling be that it that matter with basically available the it’s an offer, doubt - probably cost example or our you Where for we it's plays of know, practice between the of or for history going $XXX, anything family think exome which we an anticipate, a you no comprehensive two, in to and patient screening choice. otherwise those out want are And for know.

Unidentified Analyst

Thanks so guys. much,

Shelly Guyer

dramatically viable a offer business. at other The as down is drive it side the that obviously so to are us prices still us able of those COGS being enables for to

And critical so, why year. reduction coming we really last at the as being in the year COGS that's look the over and

Katherine Stueland

like only offer. thing years preventive to of adoption spent very think that broader we we add really is strong the importantly that a going panels that’s medical that past we've the translate building brand and I would into those The several

So, think to will competitive provide we us advantage help Invitae. that a

Operator

Your next Doug with Schenkel question & comes Cowen Co. from

open. Your line is

Adam Wieschhaus

to of Doug. of end takes appears Thanks the weren't questions. for behind quarters, about shift for forecast guiding yet primarily updated or because $XXX the Adam Was is around Can that you're the recognized $XX which term? the my improved revenue is increase it of QX guidance, the in I near three in some Is increase? levels. that volume you for and you This think your the over puts maybe you. QX towards remaining Based on Wieschhaus that ASC revenue that average on taking an parse the see to to XXX? it due out reimbursement Thank

Sean George

on that think I some Shelly on, I had year beginning can single we point. factors the walk through that to Shelly, revenue. the of other our would I increasing of how the confidence year, can walk went this the want to At for through that do key point pieces. revenue items QX, highlight they as the affect evolve? - primary we’ll you kind answer is the at driver of volume. That's the know

Shelly Guyer

noted the the of conservative don't tests But, have various prices. one. all also we're across - lot was history number it volume, setting We of all various across of prepared I So, in as in remarks, in those XXX a payers. and my

to so, somewhat And it unless be forward. fact changing I think see behooves us or circumstance conservative we moving a

before, to collections preview said that time ahead And of over let as that as know be But, to going we we're you those so, happens. not able to time. increase we'll we when begin

important I place. very think, that's So one

very sign place. did we also think, important I

as at partners our by and around CNP those did this And sign partnerships. pay multiple also of higher some driven mentioned they et was rate, we think cetera time a one. two, are somewhat I really areas in largely help

relationships I And pushing then would and be partnerships in numerous obviously that time talked other Medicare signed to would we about advocating forward just were see successful and ways having so, rate. think And helps too. increase this quarter, that we us last at we in that that if past

directly So could you only to I can drive point, ones where that in But our and it have think all of see at predicting we time. forward the of it those not are what move we giving this over go. we're as sight line think the levers we

Adam Wieschhaus

testing XX,XXX that Thank we that strong therefore volume growth expect mentioned You all tests all QX. testing least categories? categories across you. incremental testing you through most at is categories guidance in come to your or Should raise

Sean George

now We I expectation so would our think indicate that's as don't anything anything well. otherwise see that

Adam Wieschhaus

And expect level with Have the at there's bracket is you for if up annual so, me the that space? in of do occurring it a of month last or others reimbursement that looked meeting you CNS review. coming to at And one next agenda your codes maybe all? from impact several

Lee Bendekgey

And watch no, we you imagine. dramatic meeting expectations. yes see impact on expect a at careful as revenue we would would anything those keep of don't have this that we our And

Operator

next question from Partners. Leerink Souda with Puneet comes Your

Your open. line is

Puneet Souda

us level XXX was quick it One to I little but I the high before to but think understand the it a time turnaround terms is the and you exomes? the due in guide clarity it just year? I largely comments, my mix there on well addressed ASP before, exome. bit want And then, for the what's good of on the safe have Could volume. you but little addressed was think of of the largely is rest question as ASC assume sense thanks give the for a a on bit Is revenue majority that of question to second

Sean George

counting are those to-date happen. are solution the reimbursements as pointed that help as revenue as changes we've other equation it's mix the again influenced until as but will as on they guidance, largely by CMS out think us, things incurred - I payers and certainly the with the can that and on not So, third-party those Shelly we those volume resolves, the

we're is the pretty much factor in progress know see far. we know and consider mix obviously can - our launched you Exome panels just - influx. what kind but of is. has is other the little kind reimbursement of question was time and on do exome So, as by offerings, I'd the I’ve it's way you fast it you driver as exactly growing it a you other and increasing of these to the volume of in think, guidance turnaround get is it's a a - time, of And the know again one what the yes, annually I - than … it's pretty what Then beast Lee, current all know like exactly revenue about different so of - turnaround more I'll check in along, to so of it's think bit of major I growing a segments. some recently it been not

Lee Bendekgey

and stage to We've are X-week took found in sometime after be And and XX-week driving hopefully would that but Puneet, I as exome minimum the reducing it will we slip to of a time turnaround growth turnaround comfortable will at to in we initial delivering paddle got will driving volume not meeting the terms we customers, have and decided our I we until so guidance and to its XX-week starting been regularly we be were that true operations. the the take would a who of exome - promoting of So, we exome the year others that exceeded our will be of again streamline more for expect into was meeting gotten half our the our still launch, game. target pause a and has say off be little that to terms experience, X-week to in second we some exome actually that existing expectations we we where time.

Puneet Souda

that How last added the BioMarin of And about Biogen one, the guys year? should rest the in terms think through a you Thanks. cadence then these those. of Sarepta, just the of the have number we

Shelly Guyer

to cost partners including organizations. the great to pleased us focus the was us, area it for pull is of This was an partnership end we're used advocacy time. towards well as helps forward relegated testing. because biopharma use the of our clearly as build it high it strategically genetic of of the both network So continue - Historically of high turnaround

business provides starting perspective, we strategically volume, paid well, the really paid to a it us with testing. regularly. from get get a use we're see we shift of So to a in boost nice Clearly paradigm genetic

definitely to put behind. to going something it's we're that so And continue resources

You these approved trials, cycle FDA some a for of for for know there the are is longer, therapies. those are bit some clinical selling

we predict. to continue to hard that to are looking really grow it's So But network.

get view, relevance able support of FDA quicker the is think groups. from diagnosed importantly effect to research, the and to as with approved connect of patient network advocacy we're a I patients we're point able clinical this them that trials, therapies,

And so, and patients. clinicians this clearly help is to starting see pointing we're towards a broader network effect that that will that their ultimately

Operator

Amanda comes question from William Murphy next with Blair. Your

Your line is open.

Amanda Murphy

guess that to a discussion. I last follow-up so, And

about given brought just to this the kind talked testing you been developing. that things is and that the is just the of have, have of scale the access to one data you you've even So then

asset. I that talk kind So of how long-term that thinking about the about wanted monetizing you're just and to over

couple So deals I a recent ran even I you had and into biotech got know a while obviously that ago you've from recently. think some didn't I

and probably you asset over about So maybe a strategy kind as might of an you just broadly how evolve data talk as that just to think time?

Sean George

because think part standalone a the data exist. of - would thought say misplaced I that always not little opportunities I it’s misses if but a asset we've is question is a think building. it's great certainly a network is I the we're something business it however that

they history of connection them, consider most example whether information, disease. risk individual, oftentimes clinical that of other in context data longitudinal run, patients an surveys data exquisitely self-reported partnerships them information, the demographic to of that time, with it is of very understanding patient to is history specific surveys information. care including we clinicians, we're addition family families, really reported the and data, and well most of patients, over analysis data, up of the building. additional it's non-genetic pharma natural clinician either taking collection the the the that information the in we of It's In pieces health that care individualized that So we valuable the who's is, clinician to their a the network patient feel taking and of access information, the information access data, to as have, as to their those

data So, asset network really all as is building. the of view what that the of important we we're

what data of of valuable as said, we're all trying if I the in accomplish. standalone to As a we're context certain asset not that’s the

touch touch where be terms experiences - with the them with or So, getting getting in think touch faster, to similar help in That's groups And clinical in with it of value out. advocacy their - playing faster, seems diagnosed or is. therapies trials other to getting we we in in more market them. faster, with patients the people, can research that

is et the better, and question many platforms out on why we've have focus being Now, customer-facing natural the to needed more we more history, data been doubt, always years than family history, focused collect information, on continue we for We've to said the and surveys, asked. with that genetic - which applications more no generating information built build workflows that cetera. and will ongoing diagnose

on sure you data. to important control all it’s on - their value fine we bring. partners Again, at it’s So, important fronts, put consent. that simply from it or all all but make the is and it continuum that do our of the the data think shared what own monetized I patient’s our late, the sense own stem to think especially we the there, without the of consider we'll expressed really and a can time this probably economics do that in customers, and for point point consider network not future individual delivered And the life continue business improve to that healthcare we’ll the with in know, represents can not their just in do certainly

Amanda Murphy

Is have of don’t monetizing there’s you you of put integrated are thinking it that. data around broadly, you’re at give a there discussion way don’t how test of It way are magnitude terms if with about a know that - sort at values of can I just that of this on but data particularly seems every, kind you a know of set is but again and just been patient data just is in point, I numbers number if lot or? specifically, just clinical rate, that know, the the scale every, us done a genomic around I a sense like to mean that the your there not point. integration is much? more , this to it the every

Sean George

number much an panel, No, patients I entire work think you served how it’s something know and certainly XXX indicator kind or know think, of we it’s because about on actually has think it genomic I them probably we Gene exome, varies - the years, you on whether it’s that’s think I the genome, first certainly have data then if coming of mean should over - I have we you what not more in a directly and we then the part get information it’s much on And as how digitized with depending much developed do future. then from of the family individuals over many and is question varied their medical platform. time record either in we process. or information history, how asked and we the stay And being course, ordering engage in collected touch come have phenotypic with a of how many how

disease the all to been map are in. and the on know, we’ve depending that patient - the area over You honest, be group those operating

XX one we of now, ones data afraid so is times know think of genes I which kind number there time categories right think number have. know genes. no clean, The other something, we patients of I’m about. you And you of it’s But will of

ask it’s data the right think working metrics the about I this this think, right future what I questions be business we'll business sure. and the for of to are, think in about network to

Amanda Murphy

maybe Again, I and just is last around just one more boring, guess and reimbursement.

and to little payer guess about prior I place thinking the So a in things like while more more, about ops discussions to there efforts had that. some put ago front-end stopgaps in been

on it in growth about said terms across is you and cash something realized in else if mix sorry versus about this, I'm quarter curious actual in types as know, I you just relates the latest there there of but if there to and anything of So was you also, talked to - whether all terms be exome think will? testing, but the it’d price, anything

Sean George

Why about lives, in daily do do reimbursement let’s nothing boring reimbursement. - our don't we the and there's me first believe

- efforts by know the I prior think op kind payers one. to you really, various down I would call on what can say, that the clamp answer process So of we don't I place in kind kind of in discussed kind publicized applications year. facilitate process and to fall Q as was tools prior widely timeframe op put the or the last of of and

We have die that actually seen down.

I a couple out that insurance causing but a can in were companies. the confusion, daily part of dealing are hastily with these pretty there tools of think of of kind I and it’s kind of - rolled life general,

On slowed volume. it down hasn't the client, clearly the

of you requirements. lot get it out, fact, has In you it a Once paid faster. clean helps up it the helped actually actually iron

way I will to has and hopefully faster to going think we're bigger cleaner what of going It in a it’s bills, get more paid to and understanding to continue contribute - So continue payment.

forward. to I other time, behind of I - than the seen. think one I at that's and early this point kind the it's still there yet think anything us - think in I hand - be don't is some do on stuff so of early the think see usual going we choppiness

payer action trend And price. a is of it's we think kind think quality can expect attention as paid. space being activity, genetic I assessment more worth broader in mentioning I payer of there's more more there's definitely

code that in energy in clamp our stacking there's down definitely games typical the more of attention industry, on are those. to Some played

is that it on So, - I material that's about that providers it change. report about providers. mix network the again the then question opposed to that outer think as network only can kind general And essentially a trend it's to mix, favors think was the say we we thing in then, of - the nothing

faster. if as businesses fast as in and as annually, on All promoting at early grew growing our still certainly look mentioned exome, we months the Lee of of our it’s segments we even pulled any other one it even back you

a So, there's rapid at material clip. all real growing no they're change, mix

Operator

Kevin Instructions] with Ladenburg next DeGeeter question from Thalmann. [Operator Your comes

You may begin.

Kevin DeGeeter

pharma think go potential forward going and about Just something to with FDA.? fall do to interaction you diagnostic how kind on if your with the with partners, world that may of of you to companion framework into traditional some up to programs activity forward regulatory following offer these can working how potentially regard

Sean George

can Lee the this. I think get on details

The to we company always whether level, I it's the a highest answer of like actually to whatever at payer, want. is pharma a a or kind they point think provider out network. that whether it's

essentially You What is that's of know operate I want. whatever or partner and We customer can framework the operate answer. they like our three. regulatory it’s in kind that on to would all first think

this against that will there’s our Lee perspective question at can think a I give of point. be broader available, update an

Lee Bendekgey

says a think including benefits has a do we're looking pharma of disposition have that they're be we that more of I looking FDA support our certainly diagnostic frankly, prominent the of might of some And the and you in evidence our actually thinking it therapeutic. companion know appropriate about diagnostic. one for pharma for willing partners. companion And the a in ones. is we to you the our terms pleased announcements if the being to of be Sean customers pre-market lately kinds for And as think partner what thing a company medicine realistic of foundation to first to shown that is we're a approval

which and BRCA administer is pathogenic he all point decide patient, cancer patient excess testing term she or genetic breast the to that a side, becomes a the for on doctor clear or mutation to companion that making time PARP a by because imposes be whether medicine, if are cost we assume for is decision of a comprehensive prescription inhibitor know mainstream the healthcare companion diagnostics long diagnostic it’s as a On part - going system. particular that germline not diagnosing redundant example a useful whether in likelihood then has to should a at is

germline on to in system, pharma if as certainly really see we we're comply and don't that benefiting data that certainly a that generate we requirements. position long-term, feels but that's feel So the something the patients side, partner with comfortable healthcare the need, they the applicable or a

Kevin DeGeeter

reproductive for some just in more the two last then, the of - acquisitions At and the time of area. of Terrific year me. health one

through synergy aggressively potential of to channel. was opportunity sell you more the the hereditary called cancer revenue of areas out that One health the women's

about how potential is high-set out? that that us from synergies and use thinking provide of any playing integration an some as update just there metrics maybe can Now, component

Sean George

of That's and in profitability That definitely handful part of objectives of kind was one increase reproductive - large of move one of key growth drive of to the acquisitions primary health. were the our a those the ones. which from

the clients to fall that out that As clients and the time, carrier data will that why we’d on relationships we the know genetic getting it, after reproductive coming cancer right health is the screen somewhat along one become as come like provision the having Those be or flow. are to that selling of you to time selling area then we gap commercial really and That’s the mentioned filling version working in that Good kind which own reverse mix the testing in think direction right offerings kind expanding it that comprehensive moving questions. will reproductive with adding along addition health acquiring that’s expanded cancer segment segment, reproductive Start, expanding which kind for other are at proactive the clients, is in answer at into our shortly test with into of the you and having - in and proactive health the to and test right that table the health the carriers using clients stage fell the reproductive of in of two getting of a reproductive of NIPT, set of stakes albeit give undifferentiated. comprehensive, know screen us we're

I able been again, capable, it’s expanded know you haven’t yet. carrier not we question to really think and answer have screen we until the NIPT that

in that’s sales we out, reproductive volume year, launched accounts. hitting the of the are mentioned health we’ve this seen the think growth matter as cross-trained territories of the the have reproductive I test - in just more cancer year, the into We higher segment, but the got forces health

a to the year. of think, we thing cancer start real you three efforts, the there. synergies sell by distinct those some of But business expect kind would to I the seeing natural it’s would between end expect

Operator

call. to the Laura call to There are turn over D'Angelo the no further close questions. back I

Laura D'Angelo

today. at up catching conferences. us with our to joining forward for look everyone you Thanks We upcoming soon

Operator

today’s call. conference concludes This

now may disconnect. You

Invitae (NVTAQ) 9 May 182018 Q1 Earnings call transcript